论文部分内容阅读
本文借助Thomson Reuters Pharma信息平台,以不同靶标药物在各研发阶段的数量分布为主要参考指标,辅以相关文献和典型药物资料,对抗2型糖尿病药物的研发现状进行了统计、分析和研究(截至2012年5月),并对其可能的发展趋势和方向做出了判断和预测。得出以下主要结论:①IR是目前2型糖尿病常用药物普遍采用的靶标,但在研药物靶标正呈现多样化。②GLP-1受体和DPP-IV是新药开发最具潜力的靶标,大批新药项目在研,已上市药物也取得了巨大成功。③PPAR靶标药物已被大量研究用于2型糖尿病的治疗,在研药物关注瞄准两个以上PPAR靶点的多重激动剂,然而,一大批终止研发的PPAR新药项目以及对PPAR药物安全性的忧虑使PPAR靶标药物的研发前景蒙上阴影。④SGLT2靶标药物已有多例进入III期临床试验,距离成功只有一步,考虑到该类药物终止研发的数量较少以及还未发现明显的不良反应,SGLT2靶标药物具有较大的研发空间和良好的发展前景。⑤GK和GPR119是抗2型糖尿病领域的新兴靶标,最高研发阶段为II期临床试验。
Based on the information platform Thomson Reuters Pharma and the quantitative distribution of different target drugs in each stage of development as the main reference index, together with the relevant literature and typical drug information, the status quo of the research and development of anti-type 2 diabetes drugs was statistically analyzed and analyzed May 2012), and made judgments and forecasts on its possible development trends and directions. Draw the following main conclusions: ①IR is commonly used in the current type 2 diabetes commonly used drugs target, but the drug target is showing diversity. ② The GLP-1 receptor and DPP-IV are the most promising targets for the development of new drugs. A large number of new drug projects are under study and the drugs already on the market have also achieved great success. (3) PPAR target drugs have been extensively studied for the treatment of type 2 diabetes. In-process drugs are focused on multiple agonists targeting more than two PPAR targets. However, a large number of new PPAR drug projects that have been discontinued and concerns over the safety of PPAR drugs Prospects for the development of PPAR target drugs have been cast in the shadow. ④SGLT2 target drugs have entered the phase III clinical trials, only one step away from the success, taking into account the small number of such drugs to stop the development and no significant adverse reactions have been found, SGLT2 target drug has a large research and development space and good Prospects. ⑤GK and GPR119 are emerging targets in the field of anti-type 2 diabetes, the highest stage of development for the phase II clinical trials.